Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Cyclosporine 0.05% ophthalmic emulsion for the treatment of radiation-associated dry eye in children.

Hoehn ME, Kelly SR, Wilson MW, Walton RC.

Pediatr Blood Cancer. 2013 Jul;60(7):E35-7. doi: 10.1002/pbc.24461. Epub 2013 Jan 17.

PMID:
23335290
2.
3.

Efficacy of cyclosporine 0.05% ophthalmic emulsion in contact lens wearers with dry eyes.

Willen CM, McGwin G, Liu B, Owsley C, Rosenstiel C.

Eye Contact Lens. 2008 Jan;34(1):43-5. doi: 10.1097/ICL.0b013e3180676d44.

PMID:
18180683
4.

Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production.

Pflugfelder SC, De Paiva CS, Villarreal AL, Stern ME.

Cornea. 2008 Jan;27(1):64-9. doi: 10.1097/ICO.0b013e318158f6dc.

PMID:
18245969
5.

Topical cyclosporine-A in dry eye associated with chronic graft versus host disease.

Kurt RA, Yalçindag N, Atilla H, Arat M.

Ann Ophthalmol (Skokie). 2009 Fall-Winter;41(3-4):166-9.

PMID:
20214049
6.

Real-world utilization patterns of cyclosporine ophthalmic emulsion 0.05% within managed care.

Chiang TH, Walt JG, McMahon JP Jr, Mansfield JE Jr, Simonyi S.

Can J Clin Pharmacol. 2007 Summer;14(2):e240-5. Epub 2007 Jul 10.

PMID:
17622671
7.
8.
9.
10.

The effect of decreasing the dosage of cyclosporine A 0.05% on dry eye disease after 1 year of twice-daily therapy.

Su MY, Perry HD, Barsam A, Perry AR, Donnenfeld ED, Wittpenn JR, D'Aversa G.

Cornea. 2011 Oct;30(10):1098-104. doi: 10.1097/ICO.0b013e318206caee.

PMID:
21407074
11.

Topical 0.05% cyclosporin in the treatment of dry eye.

Perry HD, Donnenfeld ED.

Expert Opin Pharmacother. 2004 Oct;5(10):2099-107. Review.

PMID:
15461545
12.

[Topical cyclosporine for the treatment of ocular surface changes in contact lens wearers].

Egorova GB, Mitichkina TS, Fedorov AA, Shamsudinova AR.

Vestn Oftalmol. 2015 Jan-Feb;131(1):36-42. Russian.

PMID:
25872385
13.

Cyclosporine 0.05% ophthalmic emulsion for dry eye in Korea: a prospective, multicenter, open-label, surveillance study.

Byun YS, Rho CR, Cho K, Choi JA, Na KS, Joo CK.

Korean J Ophthalmol. 2011 Dec;25(6):369-74. doi: 10.3341/kjo.2011.25.6.369. Epub 2011 Nov 22.

14.

Evaluation of the effect of topical cyclosporine A with impression cytology in dry eye patients.

Yüksel B, Bozdağ B, Acar M, Topaloğlu E.

Eur J Ophthalmol. 2010 Jul-Aug;20(4):675-9.

PMID:
20155706
15.

Efficacy of topical cyclosporine A in the treatment of severe trachomatous dry eye: comment.

Tam PM, Young AL, Lam PT.

Clin Exp Ophthalmol. 2010 Jan;38(1):84-5. doi: 10.1111/j.1442-9071.2009.02221.x. No abstract available.

PMID:
20447110
16.

Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment.

Wilson SE, Perry HD.

Ophthalmology. 2007 Jan;114(1):76-9. Epub 2006 Oct 27.

PMID:
17070588
17.

Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion.

Turner K, Pflugfelder SC, Ji Z, Feuer WJ, Stern M, Reis BL.

Cornea. 2000 Jul;19(4):492-6.

PMID:
10928765
18.

Clinical review: topical ophthalmic use of cyclosporin A.

Utine CA, Stern M, Akpek EK.

Ocul Immunol Inflamm. 2010 Oct;18(5):352-61. doi: 10.3109/09273948.2010.498657. Review.

PMID:
20735287
19.

Reversibility of dry eye deceleration after topical cyclosporine 0.05% withdrawal.

Rao SN.

J Ocul Pharmacol Ther. 2011 Dec;27(6):603-9. doi: 10.1089/jop.2011.0073. Epub 2011 Oct 14.

PMID:
21999340

Supplemental Content

Support Center